0001628280-26-031238
SEC filingQ1 2026 delivered 7.5% revenue growth to $156.4M from ORLADEYO, but $701.6M operating loss reflects non-cash IPR&D expense from Astria acquisition, driving net loss of $721.8M and EPS of -$2.98.
BioCryst's Q1 2026 financials show robust top-line growth amid a transformative acquisition. Revenue reached $156.4 million, up 7.5% from $145.5 million in Q1 2025, primarily powered by increased ORLADEYO sales in the core U.S. market. This growth occurred despite the sale of the European ORLADEYO business to Neopharmed on October 1, 2025, which reduced associated cost of product sales and underscores strategic focus on high-margin U.S. operations.
Gross profit expanded 7.1% to $151.0 million, achieving an exceptional 96.6% margin versus prior-year levels. This efficiency stems from ORLADEYO's favorable product economics, where cost of product sales rose mainly with U.S. volume but was partially offset by the European divestiture. Management notes that cost of product sales also incorporates excess or obsolete inventory adjustments, yet the high margin reflects disciplined scaling of a premium-priced therapy.
Cash from operations used -$61.8 million, up from -$27.5 million, as acquisition-related and R&D activities accelerated. Management flags risks around achieving sustained profitability and potential capital raises, particularly with Astria integration challenges that could prove costlier or delay synergies. This positions BioCryst with an enriched pipeline including navenibart, but investors should monitor merger execution amid these transformative dynamics.